Clinicians, researchers and patient representatives converged on Madrid for the European Society of Medical Oncology (ESMO) Congress 2026. Attendance spanned international delegates and a broad range of specialties. Forty-eight presentations were simultaneously co-published at the meeting, and this article summaries a curated subset that the journal chose to highlight.
The meeting combined late-phase registrational work with a stream of early-phase innovation. Several presentations described antibody–drug conjugates (ADC), bispecific antibodies, and novel engineered modalities — including a first-in-class regulated induced proximity targeting chimera. The source article provided high-level descriptions; detailed numerical results and trial methods were not included in the summary.
Investigators at ESMO reported on G-HOPE-01, which the summary described as evaluating arcotatug tavatecan, an ADC directed against claudin 18.2. The article indicated that the agent was featured among compelling trial results presented outside presidential sessions. The source did not report dosing regimens, objective response rates, progression-free survival, safety data, or cohort size. Readers seeking those specifics must consult the primary abstract or publication for G-HOPE-01.
PEACE-1 and a sub-study from the PROTEUS programme were presented with further data supporting earlier use of anti-androgen therapies. The summary linked these trials together within the same presentation session. The report did not disclose trial endpoints, magnitude of benefit, or statistical analyses. In the same session, investigators also reported phase I data for JNJ-6143, described as a first-in-class RIPTAC that targets the androgen receptor and bromodomain-containing protein 4 in patients with advanced, castration-resistant prostate cancer. The article did not provide response rates, duration of response, or adverse-event profiles for JNJ-6143.
Early clinical activity was reported for combinations of novel immune- and tumour-targeted agents. The PD-L1 × VEGFA bispecific antibody pumitamig was combined with the B7-H3-targeted ADC elfetabart drozuntecan, and presenters described activity in patients with a range of advanced solid tumours. The summary framed this combination as promising, but did not supply objective measures of efficacy, safety grading, or patient-selection criteria. Without those data in the highlight, the clinical applicability remains to be evaluated against the full datasets.
The meeting included encouraging early-phase data for bispecific ADCs. The agents named in the summary were HS-20122 (targeting EGFR × MET) and IBI3001 (targeting EGFR × B7-H3). The study team observed activity in these trials, according to the article. The source, however, omitted methodological details — for example, specific tumour types enrolled, lines of therapy, objective response rates, and toxicity spectra — all of which are essential to interpret early clinical signals.
Phase III evidence for a B7-H3-targeted ADC, tambotatug pelitecan, was presented from the TAISHAN-301 trial. The summary stated that the trial involved patients with heavily pre-treated recurrent and/or metastatic nasopharyngeal carcinoma and that the phase III data demonstrated efficacy. The highlight did not include numerical outcome data, safety endpoints, hazard ratios, confidence intervals, or prespecified primary endpoints. Those quantitative trial elements were not reported in this meeting summary and require consultation of the full TAISHAN-301 publication or conference abstract.
This Nature Reviews Clinical Oncology research highlight functions as a concise meeting summary rather than a source of full trial reports. The article repeatedly noted activity or efficacy for several agents, yet it did not provide specific efficacy metrics, safety data, dosing information, cohort sizes, or statistical analyses for the trials mentioned. The summary indicated that forty-eight presentations were co-published and that a selection is covered elsewhere in the journal; however, anyone needing granular trial methodology or outcomes should access the primary trial publications, conference abstracts, or the full presentations.
Unanswered questions flagged by the source include the magnitude and durability of observed responses, comparative safety profiles across these novel agents, and the precise patient populations that drove the reported signals. The article did not report regulatory milestones or submission plans for these therapies. For definitive interpretation and clinical application, readers must review the primary data sources referenced at the conference.